| Code | Description | Claims | Bene. Records | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,085 |
1,847 |
$167K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
885 |
381 |
$129K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,777 |
1,618 |
$102K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
595 |
552 |
$77K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,079 |
1,016 |
$47K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
305 |
298 |
$30K |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
286 |
286 |
$15K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
173 |
172 |
$11K |
| 93000 |
|
479 |
471 |
$5K |
| 93923 |
|
50 |
50 |
$4K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
338 |
338 |
$3K |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
127 |
127 |
$2K |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
129 |
128 |
$1K |
| 94010 |
|
50 |
49 |
$1K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
43 |
43 |
$527.11 |
| 81002 |
|
226 |
216 |
$438.19 |
| 82948 |
|
157 |
150 |
$426.29 |
| 80061 |
Lipid panel |
43 |
43 |
$366.82 |
| 80053 |
Comprehensive metabolic panel |
47 |
47 |
$307.96 |
| 81025 |
|
59 |
59 |
$306.87 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
49 |
49 |
$281.91 |
| 84443 |
Thyroid stimulating hormone (TSH) |
25 |
25 |
$230.08 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
25 |
18 |
$212.64 |
| 99406 |
|
17 |
17 |
$97.70 |
| 82043 |
|
13 |
13 |
$55.45 |
| 82947 |
|
21 |
21 |
$13.40 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
158 |
156 |
$0.00 |
| Q0111 |
Wet mounts, including preparations of vaginal, cervical or skin specimens |
43 |
43 |
$0.00 |
| 1111F |
|
12 |
12 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
28 |
27 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
107 |
107 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
202 |
201 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
189 |
185 |
$0.00 |
| 99497 |
|
49 |
49 |
$0.00 |